Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.

被引：0
|
作者：
Armstrong, Andrew J.
Lin, Ping
Higano, Celestia S.
Sternberg, Cora N.
Sonpavde, Guru
Tombal, Bertrand F.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Phase III SYNERGY trial: Docetaxel ± custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent A.
    Reeves, James Andrew
    Feyerabend, Susan
    Gravis, Gwenaelle
    Ferrero, Jean-Marc
    Jacobs, Cindy
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Enzalutamide in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
    Pu, Yeong-Shiau
    Ahn, Hanjong
    Han, Weiqing
    Huang, Shu-Pin
    Wu, Hsi-Chin
    Ma, Lulin
    Yamada, Shunsuke
    Suga, Kazutaka
    Xie, Li-Ping
    ADVANCES IN THERAPY, 2022, 39 (06) : 2641 - 2656
  • [43] LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Wang, Wei
    Kwon, Young Suk
    Su, Lixiao
    Kim, Isaac Yi
    Lu, Shou-En
    JOURNAL OF UROLOGY, 2017, 197 (04): : E765 - E765
  • [44] Prognostic value of serum and rogens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data
    Ryan, Charles J.
    Molina, Arturo
    Li, Jinhui
    Kheoh, Thian San
    Small, Eric Jay
    Haqq, Christopher M.
    Grant, Russell P.
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [45] Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer
    Dong, Baijun
    Fan, Liancheng
    Wang, Yanqing
    Chi, Chenfei
    Ma, Xiaowei
    Wang, Rui
    Cai, Wen
    Shao, Xiaoguang
    Pan, Jiahua
    Zhu, Yinjie
    Xun Shangguan
    Xin, Zhixiang
    Hu, Jianian
    Xie, Shaowei
    Kang, Xiaonan
    Zhou, Lixin
    Xue, Wei
    PROSTATE, 2017, 77 (13): : 1373 - 1380
  • [46] Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
    Hahn, A. W.
    Tidwell, R. S.
    Surasi, D. S.
    Msaouel, P.
    Efstathiou, E.
    Zurita-Saavedra, A. J.
    Tu, S-M.
    McQuade, J. L.
    Fogelman, D.
    Starbuck, M. W.
    Subudhi, S. K.
    Corn, P.
    Pilie, P. G.
    Aparicio, A.
    Logothetis, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S538 - S538
  • [47] Overall survival by race and ethnicity among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population
    Freedland, Stephen J.
    Davis, Matthew
    Epstein, Andrew J.
    Arondekar, Bhakti
    Ivanova, Jasmina I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 144 - 144
  • [48] Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)
    Fizazi, K.
    Hotte, S. J.
    Saad, F.
    Alekseev, B.
    Matveev, V. B.
    Flechon, A.
    Gravis, G.
    Joly, F.
    Chi, K. N.
    Malik, Z.
    Stewart, P.
    Jacobs, C.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC)
    Vestris, Pierre-Gilles
    Gourtaud, Gilles
    Senechal, Cedric
    Sadreux, Yvanne
    Roux, Virginie
    Blanchet, Pascal
    Brureau, Laurent
    PROSTATE, 2022, 82 (02): : 269 - 275
  • [50] EARLY NEUTROPENIA IS ASSOCIATED WITH SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHEN TREATED WITH CABAZITAXEL: AN ANALYSIS OF TROPIC PHASE III TRIAL
    Meisel, A.
    von Felten, S.
    de Bono, J. S.
    De Wit, R.
    Sartor, O.
    Stenner-Liewen, F.
    ANNALS OF ONCOLOGY, 2014, 25
12345